Primary central nervous system lymphoma
Information
- Disease name
- Primary central nervous system lymphoma
- Disease ID
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT05036577 | Active, not recruiting | Phase 1 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL | October 10, 2021 | September 30, 2024 |
| NCT00863460 | Active, not recruiting | Phase 2 | Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue for Primary Central Nervous System Lymphoma in Young Patients | October 3, 2008 | May 2026 |
| NCT06115824 | Active, not recruiting | A Retrospective Study of Newly-diagnosed PCNSL Treated With a Methotrexate (MTX) and Orelabrutinib-based Regimen | August 10, 2023 | September 30, 2024 | |
| NCT04845139 | Active, not recruiting | N/A | A Case Study of Nivolumab for Relapsed/Refractory Primary Central Nervous System Lymphoma | July 2, 2022 | November 30, 2022 |
| NCT01647971 | Completed | Phase 1/Phase 2 | Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | July 19, 2012 | May 2015 |
| NCT04934579 | Completed | Phase 2 | Rituximab,Methotrexate and Lenalidomide in Newly Diagnosed Primary Central Nervous System Lymphoma | January 1, 2020 | November 15, 2022 |
| NCT00112593 | Completed | N/A | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer | November 1999 | |
| NCT02301364 | Completed | Phase 2 | Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) | November 20, 2014 | October 11, 2016 |
| NCT01421524 | Completed | Phase 1 | Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma | September 12, 2011 | November 21, 2023 |
| NCT00193973 | Completed | Phase 2 | Idarubicin Based Combined Modality Therapy in Primary CNS Lymphoma | July 2001 | August 2013 |
| NCT02669511 | Completed | Phase 2 | PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | November 12, 2015 | January 12, 2018 |
| NCT03255018 | Completed | Phase 2 | Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas | February 15, 2018 | June 29, 2023 |
| NCT05347641 | Not yet recruiting | Phase 2 | Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma | June 1, 2022 | June 1, 2029 |
| NCT06454266 | Recruiting | Phase 2 | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | December 28, 2021 | June 30, 2027 |
| NCT02203526 | Recruiting | Phase 1 | Phase 1 Study of Ibrutinib and Immuno-Chemotherapy Using Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib,Rituximab (TEDDI-R) in Primary CNS Lymphoma | August 14, 2014 | June 15, 2027 |
| NCT02655744 | Recruiting | Prospective Neurobehavioral Outcomes Follow-up in Primary CNS Lymphoma Patients Treated With Cranial Radiotherapy Combined With or Without MTX-based Chemotherapy According to the Multidisciplinary Treatment Guidelines Implemented at a Single Institute | November 1, 2015 | December 31, 2025 | |
| NCT02657785 | Recruiting | Phase 2/Phase 3 | Treatment of PCNSL With R-IDARAM and Intrathecal Immunochemotherapy | September 2010 | December 2030 |
| NCT04421560 | Recruiting | Phase 1/Phase 2 | Pembrolizumab, Ibrutinib and Rituximab in PCNSL | August 1, 2020 | March 5, 2025 |
| NCT04462328 | Recruiting | Phase 1 | Acalabrutinib and Durvalumab in Primary and Secondary Central Nervous System Lymphoma | April 29, 2021 | October 31, 2030 |
| NCT04737889 | Recruiting | Phase 2 | Rituximab, Lenalidomide Combined With Methotrexate and Temozolomide For Primary Central Nervous System Lymphoma | January 13, 2021 | January 13, 2026 |
| NCT04831658 | Recruiting | Phase 1/Phase 2 | A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | March 29, 2021 | September 15, 2024 |
| NCT04906096 | Recruiting | Phase 2 | Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL | June 1, 2021 | December 1, 2026 |
| NCT04931368 | Recruiting | Phase 3 | OptiMATe: De-escalated Induction Treatment in Primary CNS Lymphoma | June 7, 2021 | May 2028 |
| NCT05135858 | Recruiting | Phase 1 | Dose Dense Re-challenge of High Dose Methotrexate With Glucarpidase for Relapsed Primary Central Nervous System Lymphoma | September 15, 2022 | July 31, 2025 |
| NCT05334238 | Recruiting | Phase 3 | Orelabrutinib Maintenance Therapy After ASCT in Primary Central Nervous System Lymphoma | December 1, 2021 | May 30, 2025 |
| NCT05351593 | Recruiting | Phase 1/Phase 2 | Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma | June 8, 2022 | June 30, 2026 |
| NCT05390749 | Recruiting | Phase 2 | Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL | April 11, 2022 | April 1, 2026 |
| NCT05390814 | Recruiting | Phase 1 | [18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma | December 18, 2023 | June 15, 2025 |
| NCT05485753 | Recruiting | Phase 1/Phase 2 | A Study of GNC-038, a Tetra-specific Antibody, in Patients With Central Nervous System Lymphoma (PCNSL) and Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL) | February 10, 2023 | May 2025 |
| NCT05549284 | Recruiting | Phase 2 | Orelabrutinib,Rituximab and Methotrexate in Newly-diagnosed Primary Central Nervous System Lymphoma(PCNSL) | June 1, 2022 | May 30, 2026 |
| NCT05600660 | Recruiting | Phase 2 | Orelabrutinib,Rituximab and Methotrexate in Newly Diagnosed Primary Central Nervous System Lymphoma | August 1, 2022 | December 31, 2027 |
| NCT05681195 | Recruiting | Phase 2 | Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | April 25, 2024 | February 2031 |
| NCT06175000 | Recruiting | Phase 2 | Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response | March 13, 2024 | September 15, 2029 |
| NCT06445257 | Recruiting | N/A | A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSL | September 15, 2023 | April 30, 2026 |
| NCT02836158 | Recruiting | Phase 2/Phase 3 | Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With PCNSL | September 2010 | December 2030 |
| NCT03495960 | Recruiting | Phase 2 | Study on Tailored Treatment in Elderly Patients With Newly Diagnosed Primary Lymphoma of Central Nervous System | June 15, 2019 | December 31, 2024 |
| NCT04070040 | Recruiting | Phase 2 | Camrelizumab for Patients With Recurrent Primary Central Nervous System Lymphoma (PCNSL) | February 13, 2020 | December 31, 2024 |
| NCT04120350 | Recruiting | Phase 1/Phase 2 | R2-MTX With Lenalidomide Maintenance in Newly-diagnosed PCNSL：a Multicenter Phase Ib/II Stuty | August 16, 2019 | August 2024 |
| NCT01944943 | Terminated | Phase 2 | Phase II Study of Vismodegib in Patients With Refractory or Relapsed B-cell Lymphoma or Chronic Lymphocytic Leukemia | February 2013 | October 2014 |
| NCT02113007 | Terminated | Phase 2 | Study of High-Dose Rituximab With Temozolomide as Treatment for Primary Central Nervous System (CNS) Lymphoma | July 2014 | February 2016 |
| NCT02399189 | Unknown status | Phase 2 | MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma | May 2014 | April 2019 |
| NCT02313389 | Unknown status | Phase 3 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma | September 2015 | April 2023 |
| NCT03582254 | Unknown status | N/A | Role of [18F]-FDG Brain PET in Newly Diagnosed Primary Cerebral Lymphoma, in Immunocompetent Patient Older Than 60 Years | June 13, 2016 | May 12, 2023 |
| NCT03733327 | Unknown status | Phase 2/Phase 3 | BUCYE Conditioning Regimen for PCNSL Undergoing Auto-HSCT | November 2018 | October 2021 |
| NCT02779101 | Unknown status | Phase 2 | Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) | June 2016 | June 2019 |
| NCT04899427 | Unknown status | Phase 2 | Phase II Study of Orelabrutinib Combined With PD-1 Inhibitor in Relapsed/Refractory Primary Central Nervous System Lymphoma | March 24, 2021 | October 24, 2023 |
| NCT04083066 | Unknown status | Phase 4 | Open Randomized Prospective Clinical Study of R-FPD Versus R-MAD Regimen in the Treatment of Primary Central Nervous System Lymphoma | September 5, 2019 | April 1, 2024 |
| NCT00455286 | Unknown status | Phase 2 | a Phase II Study in Primary Central Nervous System Lymphoma | November 2006 | November 2011 |
| NCT04066920 | Unknown status | Phase 2 | IBER Salvage Treatment Followed by Ibrutinib Maintenance for Relapsed or Refractory PCNSL | October 1, 2019 | September 30, 2023 |
| NCT02983942 | Unknown status | Phase 1/Phase 2 | Ketogenic Diet Adjunctive to HD-MTX Chemotherapy for Primary Central Nervous System Lymphoma | January 2017 | December 2019 |
| NCT04457869 | Unknown status | Phase 2 | A Study of F520 in Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL) or Secondary Central Nervous System Lymphoma (SCNSL) | November 1, 2020 | January 1, 2023 |
| NCT04514393 | Unknown status | Phase 2 | Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma | October 10, 2020 | June 1, 2024 |
| NCT03120000 | Withdrawn | Phase 2 | PQR309 in Phase 2 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma | December 2017 | December 2019 |
| NCT00712062 | Withdrawn | Phase 2 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System Lymphoma | February 2009 | February 2010 |
| NCT00003505 | Withdrawn | Phase 2 | Antineoplaston Therapy in Treating Patients With Primary Central Nervous System Lymphoma |
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0030069
- OrphaNumber from OrphaNet (Orphanet)
- 46135